• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.910 -0.040 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,263,704
Open 1.960
Bid (Size) 1.880 (500)
Ask (Size) 1.920 (16,100)
Prev. Close 1.950
Today's Range 1.870 - 1.965
52wk Range 1.105 - 2.700
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
January 06, 2026
From Cellares Corp
Via Business Wire
News headline image
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
January 06, 2026
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications 
From Autolus Therapeutics plc
Via GlobeNewswire

Performance

YTD
+2.1%
+2.1%
1 Month
+28.2%
+28.2%
3 Month
+8.5%
+8.5%
6 Month
-23.0%
-23.0%
1 Year
-20.7%
-20.7%

More News

Read More
News headline image
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
December 08, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2025 ↗
November 12, 2025
Via Benzinga
News headline image
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
December 08, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
December 01, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK ↗
November 25, 2025
Via Stocktwits
News headline image
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
November 25, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 13, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
November 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
A Look at Autolus Therapeutics's Upcoming Earnings Report ↗
November 11, 2025
Via Benzinga
News headline image
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
November 03, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
October 30, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
October 27, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
October 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 15, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
September 16, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
August 12, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For August 12, 2025 ↗
August 12, 2025
Via Benzinga
News headline image
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
July 24, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
July 21, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗
June 30, 2025
Via Benzinga

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?
Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?
Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?
The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market
What is the current price of Autolus Therapeutics plc - American Depositary Shares?
The current price of Autolus Therapeutics plc - American Depositary Shares is 1.910
When was Autolus Therapeutics plc - American Depositary Shares last traded?
The last trade of Autolus Therapeutics plc - American Depositary Shares was at 01/08/26 04:00 PM ET
What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?
The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 99.98M
How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?
Autolus Therapeutics plc - American Depositary Shares has 100M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap